The challenge of acute myeloid leukemia in older patients

Current Opinion in Oncology

Volumn 14, Issue 1, 2002, Pages 24-30

  Sekeres, Mikkael A ^a   Stone, Richard M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IDARUBICIN; MITOXANTRONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; FEVER; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; IMMUNOMODULATION; LEUKEMIA REMISSION; MUCOSA INFLAMMATION; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ACUTE DISEASE; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; PALLIATIVE CARE; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0036148898     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200201000-00005     Document Type: Review

References (78)

1. The genetics of AML: An update
2. Epidemiology and hereditary aspects of acute leukemia
3. Cancer statistics, 2001, in CA
4. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases
5. Myelodysplastic syndromes: A study of 101 cases according to the FAB classification
6. Myelodysplastic syndromes: Analysis of 131 cases according to the FAB classification
7. Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases
8. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
9. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997
10. How I treat older patients with AML
11. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
12. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients
13. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
14. Isolated trisomy (IT) is an adverse prognostic factor in patients (Pts) with AML: Results from Cancer and Leukemia Group B (CALGB 8461)
15. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
16. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
17. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia
18. Revised classification of acute myeloid leukemia
19. Management of acute myeloid leukemia in elderly patients
20. Acute myeloid leukemia in the Elderly: 159 Nagoya case studies-Nagoya Cooperative Study Group for elderly leukemia
21. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
22. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GIMEMA AML 8A trial
23. Tailoring the treatment of acute myeloid leukemia
24. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: Results from the MRC's 9th AML trial
25. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
26. De novo and secondary acute myeloid leukemia in patients over the age of 65: A review of fifty-six successive and unselected cases from a general hospital
27. Intensive postremission chemotherapy in adults with acute myeloid leukemia
28. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial
29. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B
30. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency
31. Risk factors for high-dose cytarabine neurotoxicity: An analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia
32. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group
33. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A cancer and leukemia group B study
34. Dose intensification in acute myeloid leukaemia: Greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study
35. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
36. Varying intensity of postremission therapy in acute myeloid leukemia
37. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A southwest oncology group study (9031)
38. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group
39. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients
40. Etoposide in acute nonlymphocytic leukemia
41. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
42. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study
43. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group
44. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly
45. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly
46. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study
47. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report
48. Idarubicin including regimens in acute myelogenous leukemia in elderly patients
49. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study
50. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
51. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75
52. Treatment of acute myelogenous leukaemia in patients aged 50-65: Idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course
53. High-dose cytarabine and idarubicin induction produces a high complete remission (CR) rate in previously untreated de novo acute myeloid leukemia (AML) patients (Pts) >60 years old
54. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia
55. A Phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 years) with acute myelogenous leukemia (AML): A study of the Eastern Cooperative Oncology Group (E3993)
56. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia
57. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A southwest oncology group study 9617
58. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial
59. Multidrug resistance modulation in vivo: The effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia
60. Nonablative allogeneic hematopoietic stem cell transplantation
61. Post-remission therapy in older patients with de novo acute myeloid leukemia (AML): A randomized trial comparing mitoxantrone/intermediate dose cytarabine with standard dose cytarabine (CALGB study 8923)
62. Aggressive salvage treatment is not appropriate for most elderly patients with acute myeloid leukemia relapsing from first complete remission
63. Antibody-targeted therapy for myeloid leukemia
64. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
65. Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates
66. Monoclonal antibodies to the myeloid stem cells: Therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate
67. Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) in patients with CD33-positive acute myeloid leukemia in first relapse
68. Comparison of the efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients <60 and >60 years of age with AML in first relapse
69. New developments in the treatment of acute myeloid leukemia
70. Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia
71. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
72. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
73. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia
74. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: An Eastern Cooperative Oncology Group Trial (E5483)
75. Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemia: Preliminary results of a phase I trial
76. Clinical and biologic activity of the farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
77. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: A new approach to anti-leukemia therapy